BeOne Medicines AG (ONC) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-26
Business type: Asset play
How it makes money
BRUKINSA drives earnings by proving clinical superiority over ibrutinib, allowing it to capture $3.9 billion in sales as the leading treatment for B-cell malignancies.
The company relies on BRUKINSA for the vast majority of its revenue, generating $3.9 billion out of $5.3 billion total sales in 2025. It captures market share from incumbents because it is the only inhibitor in its class to demonstrate superior efficacy and lower cardiac toxicity in head-to-head trials against the former standard, ibrutinib.
Profitability is driven by global expansion into 77 markets and inclusion in reimbursement lists like the NRDL in China. Every unit sold helps fund a transition into a broader hematology franchise that now includes newly approved BCL2 inhibitors and a pipeline of protein degraders.
What protects it: the moat
It maintains an internal clinical team of 3,800 people to achieve faster proof-of-concept and lower development costs than rivals who rely on external agencies.
The company protects its margins through a structural rejection of the industry-standard outsourcing model. By managing clinical trials internally across six continents, it claims to avoid the high markups and scheduling delays associated with contract research organizations (CROs).
This "superhighway" allows the company to run large-scale, multi-regional trials that support diverse data collection, making it difficult for smaller biotech rivals to match its speed in bringing second-generation oncology treatments to market.
What growth costs
The company spent $2.1 billion on R&D in 2025 to support its internal clinical infrastructure and a pipeline of 20 protein degrader programs.
Growth is capital-intensive, requiring $2.1 billion in annual R&D spending to maintain its internal clinical operations and manufacturing facilities. Over 75% of the total cost of bringing its medicines to patients is tied to these clinical trials.
Investment is focused on lifecycle management for BRUKINSA and advancing a pipeline of more than 20 chimeric degradation activation compounds (CDACs). The company also maintains a $1.0 billion debt load to finance its global manufacturing footprint, including a new clinical R&D facility in New Jersey.
What could damage it
Price bidding for China's National Reimbursement Drug List or US regulatory price caps could force deep discounts that impair the margins of core drugs.
The business is uniquely exposed to centralized pricing negotiations. In China, inclusion on the National Reimbursement Drug List (NRDL) often requires significant discounts to list prices. If the company fails to win these negotiations or is forced into aggressive price bidding for non-exclusive drugs, its primary revenue streams in the region would be permanently impaired.
In the U.S., the Inflation Reduction Act places similar pressure on innovators, potentially capping the price of top-selling oncology brands and reducing the long-term return on R&D investment.
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.